What if we could predict which cancer mutations actually drive growth, before they show up in patients?
Researchers at The University of Edinburgh has delivered with a first-of-its-kind, mutation-by-mutation map of a key cancer gene (CTNNB1), the one that controls β-catenin signaling. Most of us in science and biotech talk about “mutations” like they’re all equally bad. They’re not. Some barely move the needle. Others kick growth into high gear. Until now, we didn’t have a complete experimental picture of how every possible mutation in this hotspot behaved. Here’s what makes this work stand out: • 342 single-letter gene changes tested every one in engineered stem cells. • The results were directly compared to real tumor data from thousands of patients and the lab scores lined up with what actually happens in people. • They showed that the strength of a mutation matters: weaker ones in liver cancer linked with more immune cell presence, stronger ones with “colder” tumors. This isn’t an academic exercise. It’s a practical map that helps answer questions we face every day in precision oncology: 👉 Which mutations are worth chasing? 👉 Which ones are just noise? 👉 How might a specific mutation influence immune response or therapy choice? It’s also a reminder that comprehensive functional data still matters, even in an era of big genomic databases and AI predictions. Knowing how a mutation behaves gives us context that sequence data alone can’t. If you’re working in cancer research, computational biology, drug development, or clinical genomics. This kind of systematic functional profiling is the kind of tool you want in your toolkit.